Key result
Elevated Lipoprotein(a) serves as an independent risk factor for cardiovascular diseases and calcified aortic valve disease, with emerging RNA therapies showing promise for lowering its levels.
Answers are grounded in this paper and cite their sources.
This review highlights the role of Lipoprotein(a) as an independent cardiovascular risk factor and summarizes current and emerging therapeutic strategies to lower its levels.
Extensive research on Lipoprotein(a) (Lp(a)) levels and their link to morbidity and mortality in regard to cardiovascular risk remains a cornerstone of cardiovascular studies. Recent findings suggest that in younger patients, Lp(a) serves as an independent risk factor for cardiovascular diseases (CVD). This is mediated by diverse processes, including signaling processes driving angiogenesis, cellular Inflammation and proliferation, cytokine formation, and antifibrinolytic activity. In addition, Lp(a) mediates the atherogenic properties of low-density lipoprotein (LDL). Studies have shown worse long-term CVD morbidity and mortality outcomes, including acute myocardial infarction (MI), coronary atherosclerosis, and stroke in individuals with elevated plasma Lp(a) concentrations. In recent times, studies have also suggested a link between Lp(a) levels and calcified aortic valve disease (CAVDs), indicating that higher Lp(a) levels are associated with a faster progression of aortic stenotic valvular disease. In this review article, we discussed the effects of lifestyle modification, such as nutrition and exercise, on Lp(a) concentration, with a recommendation to promote novel therapeutic approaches to reducing Lp(a) levels. Given the significance of predicting atherosclerotic cardiovascular disease (ASCVD) risk through Lp(a) measurement, its importance cannot be overstated. The Lp(a) lowering effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) mAbs and lipoprotein apheresis has been well established. In contrast, the effects of statins, fibrates, ezetimibe, niacin, and bempedoic acid on Lp(a) levels have been inconsistent. New emerging therapies with significant promise target RNA molecules to modify protein production and lower Lp(a). Further research is required to facilitate modalities to explore Lp(a) further and tackle cardiovascular morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Tabowei et al. (2025) conducted a review in Cardiovascular disease. Lipoprotein(a) was evaluated. Elevated Lipoprotein(a) serves as an independent risk factor for cardiovascular diseases and calcified aortic valve disease, with emerging RNA therapies showing promise for lowering its levels.
Synapse has enriched 10 related papers. Consider them for comparative context: